Moss Gregory S. 4

What Happened
Gregory S. Moss, Evommune’s Chief Business & Legal Officer, exercised 14,223 stock options and immediately sold the 14,223 resulting shares on May 28, 2026. The options were exercised at an aggregate cost of $24,321 (exercise price $1.71 per share) and the shares were sold at a weighted average price of $22.83 per share for aggregate proceeds of approximately $324,711. The filing also reports the derivative instrument as disposed (reported at $0), reflecting the option conversion/settlement.

Key Details

• Transaction date: 2026-05-28; Form 4 filed 2026-06-01 (appears timely — within two business days).
• Exercise: 14,223 shares acquired at $1.71 per share (total $24,321).
• Sale: 14,223 shares sold at a weighted average price of $22.83 per share (total ≈ $324,711); sale prices ranged from $22.50 to $23.42.
• Derivative: 14,223 reported as disposed at $0 consistent with conversion of the option.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted Feb 26, 2026 (F1); securities are held by a family trust of which Moss is trustee and he disclaims beneficial ownership except for pecuniary interest (F3); option vesting schedule disclosed (F4).

Context
This was effectively a cashless exercise and immediate sale under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce questions about timing. The 10b5-1 plan and trust holding are disclosed in the filing, so the activity appears structured rather than a spontaneous market-timing decision.